The Canary Sings Part 1

Chapter 099: The Canary Sings Part 1 Sarah Chen put Catherine Marsh's name on the SEC response board before Leah had finished taking off her coat. The magnetic strip beside the conference table held seven names, each matched to a disclosure risk. Catherine's sat under NexGen Therapeutics, directly beneath the words FDA correspondence / acquisition disclosures. Around her, the west side of the thirty-fourth floor had stopped pretending this was ordinary portfolio work. Four analysts were already hunched over filings. Two senior associates argued in low voices about version control. Sarah, sharp-eyed and quick, tapped the board with a marker and said, "If the 2023 10-K missed something material, I want to know before Legal asks why we did not." Leah kept Catherine's face still. "Understood." The assignment was legitimate enough to make it dangerous. Catherine Marsh was supposed to review every public Costa Holdings disclosure tied to the NexGen acquisition: annual reports, quarterly updates, investor decks, press releases, and call transcripts. The work gave her a sanctioned reason to search for the very omission Isabella needed. It also put her search inside a monitored crisis team, under Sarah Chen's deadline and David Choi's expectations. "You have the filings?" Sarah asked. Leah lifted the stack beside her laptop. "Printed and digital." "Good. Start with the 2023 10-K. I want anything that could be read as incomplete, softened, or inconsistent with internal acquisition records." "How broad is 'inconsistent'?" Sarah's mouth tightened. "Broad enough to keep us alive." That was the closest anyone at Thorne Group had come to admitting fear. Leah took the cubicle assigned to her on the west side, separate from Market Analysis, where the crisis team had turned a normal workspace into a paper storm. Costa Holdings binders leaned against monitor stands. Printed SEC rules lay open beside stale coffee. A whiteboard listed dates: NexGen LOI, internal due diligence close, FDA inspection letter, board approval, acquisition announcement, March 2024 filing. The dates were a trap Martha's people had built for themselves. Leah opened the 10-K first, because public filings did not forget unless someone taught them how. For ninety minutes, Catherine Marsh did exactly what a diligent junior analyst should do. She matched the acquisition summary to investor slides. She checked risk factors for clinical trial language. She compared press-release phrasing against the cleaned ThorneVault model David had permitted her to use. She made bland notes in the shared team file and sharper ones in a private scratch document she would delete before leaving. At 10:45, the omission appeared. The 2023 10-K described NexGen as a strategic acquisition with "promising late-stage trial outcomes" and "strong regulatory positioning." It discussed projected return, therapeutic category growth, and expected FDA approval timing. It did not mention the FDA inspection letter. It did not mention the 3.7 percent discrepancy between raw patient records and reported trial outcomes. It did not mention that senior executives had known about the discrepancy before closing. Leah read the paragraph three times. The silence around her seemed to sharpen. There it was: not hidden in an archive, not buried under Pemberton's private files, but missing in public, where every investor had been invited to believe the lie. The absence was its own evidence. A reasonable investor would have wanted to know whether the largest healthcare acquisition in the portfolio had a clinical-trial integrity problem and whether the executives had known before paying three hundred forty million dollars. But absence alone would not convict anyone. The omission had to be deliberate. Someone had to choose not to disclose. Someone had to see the FDA letter, understand the 3.7 percent problem, and decide the acquisition narrative would remain clean. The ThorneVault chain gave Leah names: Antonio Costa, Sebastian Costa, Howard Pemberton, Martha Thorne. What it did not yet give her was the channel between knowledge and public filing. Legal could call it judgment. Finance could call it immaterial. Martha could call it governance. In court, words like that became velvet gloves over knives. Leah bookmarked the section, saved the page number, and copied the disclosure language into her private scratch file. Then she made the safe note Sarah Chen expected: No FDA inspection-letter reference located in 2023 10-K acquisition disclosure; compare against internal due diligence chronology. Sarah passed behind her cubicle fifteen minutes later and stopped. "Already found something?" "A possible gap," Leah said. Sarah leaned over the cubicle wall just enough to see the page. "NexGen?" "The filing references clinical strength and approval timeline. I have not found any public reference to the inspection letter or the data-variance issue." Sarah's expression changed by less than a breath, but Leah caught it. Not surprise. Confirmation. "Document it cleanly," Sarah said. "Do not characterize intent." "Of course." "And Catherine?" Leah looked up. "Do not discuss that gap outside this team." The warning should have closed the subject. Instead, it told Leah the omission had already made people nervous. She nodded, waited until Sarah moved on, and returned to the filing with the pulse of a small victory under her ribs. The lie had left a public outline. Now she needed someone inside Thorne Group who could prove the outline had been drawn by hand. At 12:30, Leah carried a cafeteria tray toward the window tables and found Rachel Okonkwo sitting alone with a salad, an iPad, and the rigid stillness of a woman who had learned to keep her face locked while rooms shifted around her. Rachel did not look up until Leah stopped beside her. "May I?" For half a second Rachel assessed the tray, the badge, the borrowed face, and whatever she had already heard about Catherine Marsh. Then she moved her iPad three inches to the left. "Of course." Leah sat. The cafeteria noise rose around them, useful and ugly: silverware, printer gossip, crisis-team speculation, the flat laugh of people pretending SEC did not mean danger. For two minutes they ate without speaking. Leah let the silence become ordinary. Rachel broke it first. "You were in the executive briefing." "Yes." "Your NexGen variance slide was technically correct." Leah set down her fork. "That sounds like the beginning of an objection." Rachel's eyes lifted, sharp enough to cut through Catherine's calm. "It is. You framed the 3.7 percent variance as a manageable data-quality issue. That is what the room needed to hear. It is not what the data means." Leah kept her voice mild. "I presented the information available in ThorneVault." "Then ThorneVault is presenting a story." Rachel leaned back, but her voice dropped. "A variance that low can be more suspicious than a high one if someone cleaned the record before reporting it. You know that, or you would not have asked Sarah for the pre-closing chronology." The fork in Leah's hand became very still. Rachel's gaze flicked toward the crisis-team cubicles. "In 2018, I worked on Veritas Labs. Due diligence came back incomplete. A report was truncated. David said the directive came from above his pay grade. I filed an internal ethics complaint. HR dismissed it. Two months later, I was moved out of deal work." There was Leah's canary, not singing yet, but opening its throat. "Why tell me?" Leah asked. "Because you are new," Rachel said, "but you are not naive. And if the 2023 filing omitted what I think it omitted, someone inside this building has started a fire Martha Thorne may not be able to smother."